UCB SL0044
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
- Investigator
- Michael R Bubb
- Status
- Accepting Candidates
- Ages
- 16 Years - N/A
- Sexes
- All
Determine effectiveness of Anifrolumab In SYstemic sclerosis (DAISY)
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013…
- Investigator
- Michael R Bubb
- Status
- Accepting Candidates
- Ages
- 18 Years - 70 Years
- Sexes
- All
AbbVie-M23-699
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active…
- Investigator
- Michael R Bubb
- Status
- Accepting Candidates
- Ages
- 18 Years - 63 Years
- Sexes
- All